A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for Breast Cancer
51 locations incl. Phoenix
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06790693·Phase 3·Recruiting